BioXcel Therapeutics (BTAI) Misses Q1 EPS by 17c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($0.87), $0.17 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $582 thousand versus the consensus estimate of $440 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Citi turns more bullish on trucking stocks
• HSBC Raises S&P500 Target to 8,100
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance